FI953256A - Antihyperglykemiskt verksamt läkemedel - Google Patents

Antihyperglykemiskt verksamt läkemedel Download PDF

Info

Publication number
FI953256A
FI953256A FI953256A FI953256A FI953256A FI 953256 A FI953256 A FI 953256A FI 953256 A FI953256 A FI 953256A FI 953256 A FI953256 A FI 953256A FI 953256 A FI953256 A FI 953256A
Authority
FI
Finland
Prior art keywords
prepn
hyperglycemic drug
hyperglycemic
drug
antihyperglycaemically
Prior art date
Application number
FI953256A
Other languages
English (en)
Finnish (fi)
Other versions
FI117374B (sv
FI953256A0 (sv
Inventor
Elbert Kaan
Dieter Ziegler
Reinhard Brueckner
Original Assignee
Kali Chemie Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kali Chemie Pharma Gmbh filed Critical Kali Chemie Pharma Gmbh
Publication of FI953256A0 publication Critical patent/FI953256A0/sv
Publication of FI953256A publication Critical patent/FI953256A/sv
Application granted granted Critical
Publication of FI117374B publication Critical patent/FI117374B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
  • Fats And Perfumes (AREA)
FI953256A 1994-07-01 1995-06-30 Antihyperglykemiskt verksamma läkemedel FI117374B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4423177A DE4423177A1 (de) 1994-07-01 1994-07-01 Antihyperglykämisch wirksame Arzneimittel
DE4423177 1994-07-01

Publications (3)

Publication Number Publication Date
FI953256A0 FI953256A0 (sv) 1995-06-30
FI953256A true FI953256A (sv) 1996-01-02
FI117374B FI117374B (sv) 2006-09-29

Family

ID=6522064

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953256A FI117374B (sv) 1994-07-01 1995-06-30 Antihyperglykemiskt verksamma läkemedel

Country Status (23)

Country Link
US (1) US5712283A (sv)
EP (1) EP0689837B1 (sv)
JP (1) JP3841846B2 (sv)
KR (1) KR100366130B1 (sv)
CN (1) CN1092961C (sv)
AT (1) ATE210444T1 (sv)
AU (1) AU691580B2 (sv)
CA (1) CA2152998C (sv)
CZ (1) CZ287563B6 (sv)
DE (2) DE4423177A1 (sv)
DK (1) DK0689837T3 (sv)
DZ (1) DZ1894A1 (sv)
ES (1) ES2167385T3 (sv)
FI (1) FI117374B (sv)
HU (1) HU226946B1 (sv)
IL (1) IL113411A (sv)
NO (1) NO307029B1 (sv)
NZ (1) NZ270990A (sv)
PT (1) PT689837E (sv)
RU (1) RU2145857C1 (sv)
SK (1) SK282227B6 (sv)
UA (1) UA27954C2 (sv)
ZA (1) ZA954691B (sv)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11501020A (ja) * 1995-02-28 1999-01-26 バイエルスドルフ リリー ゲゼルシャフト ミット ベシュレンクテル ハフツング アテローム性動脈硬化症を治療するためのモキソニジンの使用
AU3233197A (en) * 1996-06-06 1998-01-05 Eli Lilly And Company Formulation and method for treating congestive heart failure
IL123232A0 (en) * 1997-02-11 1999-11-30 Lilly Co Eli Medicament for inhibiting glucose metabolism deterioration
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
EP0919234A3 (en) * 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine
US6897019B1 (en) * 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
WO2000044355A1 (en) * 1999-01-29 2000-08-03 Eli Lilly And Company Moxonidine salts
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
CA2487541A1 (en) * 2002-06-19 2003-12-31 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
AU2004283047B2 (en) * 2003-10-10 2009-09-17 Abbott Laboratories Gmbh Pharmaceutical composition comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker
RU2542462C2 (ru) * 2013-06-28 2015-02-20 Андрей Владиславович Струтынский Способ коррекции кризового течения гипертонической болезни и абдоминального ожирения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
IL113411A0 (en) 1995-07-31
CZ139395A3 (en) 1996-01-17
CZ287563B6 (en) 2000-12-13
AU691580B2 (en) 1998-05-21
US5712283A (en) 1998-01-27
KR100366130B1 (ko) 2003-03-26
HU9501900D0 (en) 1995-08-28
UA27954C2 (uk) 2000-10-16
NZ270990A (en) 1997-06-24
JPH0840906A (ja) 1996-02-13
CA2152998A1 (en) 1996-01-02
DE4423177A1 (de) 1996-01-04
FI117374B (sv) 2006-09-29
DZ1894A1 (fr) 2002-02-17
ZA954691B (en) 1996-01-29
KR960003729A (ko) 1996-02-23
JP3841846B2 (ja) 2006-11-08
EP0689837A2 (de) 1996-01-03
CN1122224A (zh) 1996-05-15
SK282227B6 (sk) 2001-12-03
HU226946B1 (en) 2010-03-29
PT689837E (pt) 2002-04-29
NO307029B1 (no) 2000-01-31
ES2167385T3 (es) 2002-05-16
EP0689837A3 (de) 1996-06-05
HUT72599A (en) 1996-05-28
NO952624D0 (no) 1995-06-30
ATE210444T1 (de) 2001-12-15
AU1775795A (en) 1996-01-18
DE59509928D1 (de) 2002-01-24
RU2145857C1 (ru) 2000-02-27
FI953256A0 (sv) 1995-06-30
IL113411A (en) 1999-07-14
SK74995A3 (en) 1996-05-08
CA2152998C (en) 2002-09-03
EP0689837B1 (de) 2001-12-12
DK0689837T3 (da) 2002-03-11
CN1092961C (zh) 2002-10-23
NO952624L (no) 1996-01-02

Similar Documents

Publication Publication Date Title
DE59010810D1 (de) Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
ES2139638T3 (es) 1,4-piperazinas disustituidas para el tratamiento de las enfermedades del sistema nervioso central y de las enfermedades neuroendocrinas.
NO960949D0 (no) Tablettert flerdoseenhetsform inneholdende protonpumpeinhibitor
FI953256A (sv) Antihyperglykemiskt verksamt läkemedel
DE59100067D1 (de) Orale arzneimittelformen von pimobendan.
EP0369887A3 (fr) Utilisation de trifluorométhylphényltétrahydropyridines pour la préparation de médicaments destinés à combattre les troubles anxio-dépressifs
EP0330052A3 (de) Verwendung von Benzimidazolen zur Herstellung eines Arzneimittels mit antiischämischen Wirkungen am Herzen und dessen Kombinationen mit Beta-Blockern oder Bradycardica
NO941036L (no) Sparfloxacinsalter og opplösninger inneholdende saltene
CA2038025A1 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
ATE127343T1 (de) Pharmazeutische zubereitung von roxindol oder carmoxirol mit vorgeqüollener stärke.
EP0471388A3 (de) Mittel zur Behandlung der Herzinsuffizienz
GR861646B (en) 4-amino-2-(imidazolidin-2-on-1-yl)-pyrimidino-5-carbonic acid -(n-triphthoro - methyl-phenyl)-amides for antithrombotic protection and treatment use and preparation of antithrombotically active medicines
ES2117114T3 (es) Nuevos derivados de tiaxolidin-diona, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
FR2610627B1 (fr) Sels cristallins de l'acide (3s(z))-2(((1-(2-amino-4-thiazolyl)-2-((2,2-dimethyl-4-oxo-1-(sulfo-oxy)-3-azetidinyl)amino)-2-oxoethylidene)-amino)oxy)acetique, a action therapeutique
DE69106276D1 (de) Säureadditionssalze einer optisch aktiven Alaninanilidverbindung und diese enthaltende, pharmazeutische Zusammensetzungen.
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
DK0631777T3 (da) Anvendelse af beta-naphtoquinonderivater til hæmning af blodpladesammenklumpning
DK0499586T3 (da) Substitueret benzofuranylpiperidin som nootropikum
JPS6434920A (en) Therapy for mycobacterium abium intracellular complex infection
FI941850A (sv) Ny förening, leustroduksin H, dess framställning och terapeutiska användning
DE3674060D1 (de) Pharmacologisch aktive propionylanilide.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: SOLVAY PHARMACEUTICALS GMBH

FG Patent granted

Ref document number: 117374

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: ABBOTT PRODUCTS GMBH

PC Transfer of assignment of patent

Owner name: ABBOTT LABORATORIES GMBH

MM Patent lapsed